Drug Profile
OCX 063
Alternative Names: OCX-063Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator OccuRx
- Class Anti-inflammatories; Eye disorder therapies; Small molecules
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic macular oedema; Diabetic retinopathy; Eye disorders; Glaucoma; Retinal disorders; Wet age-related macular degeneration
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in Australia
- 28 Mar 2024 No recent reports of development identified for preclinical development in Glaucoma in Australia
- 28 Mar 2024 No recent reports of development identified for preclinical development in Retinal-disorders in Australia